Search results :

Tenofovir

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Codes: None found

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3
Pruritus 16% x x
Fasting 2% - 24% x x x
Diarrhoea 5% - 16% 10% x x x
Nausea 7% - 20% 5% x x x
Pain 7% - 12% 7% x x x
Fatigue 8% x x x
Asthenia postmarketing, 7% - 11% 6% x x x
Depression 4% - 8% 3% x x x
Rash postmarketing, 5% - 9% 4% x x x
Vomiting 4% - 13% 1% x x x
Abdominal pain postmarketing, 4% - 22% 3% x x x
Insomnia 3% - 18% 2% x x x
Dizziness 1% - 13% 3% x x x
Headache 5% - 8% 5% x x x
Upper respiratory tract infection 5% x x x
Body temperature increased 2% - 11% 2% x x x
Neuropathy peripheral 3% - 5% 3% x x x
Sinusitis 4% x x x
Anorexia 3% - 4% 2% x x x
Back pain 3% - 4% 3% x x x
Dyspepsia 3% - 4% 2% x x x
Flatulence 3% - 4% 1% x x x
Myalgia 3% - 4% 3% x x x
Chest pain 3% 1% x x x
Glycosuria 1% - 3% 3% x x x
Nasopharyngitis 3% x x x
Sweating 3% 2% x x x
Weight decreased 2% - 4% 1% x x x
Pneumonia 2% - 3% 0% x x x
Haematuria 2% x x x
Hyperglycaemia 1% x x x
Lactic acidosis postmarketing x x x
Angioedema postmarketing x x
Connective tissue disorder postmarketing x x x
Dyspnoea postmarketing x x x
Fanconi syndrome postmarketing x x x
Fracture postmarketing x x x
Gastrointestinal disorder postmarketing x x x
Hepatitis postmarketing x x x
Hypersensitivity postmarketing x x x
Hypokalaemia postmarketing x x x
Immune system disorder postmarketing x x x
Renal failure acute postmarketing x x x
Nephrosis lower nephron postmarketing x x x
Mediastinal disorder postmarketing x x x
Myopathy postmarketing x x x
Nephritis interstitial postmarketing x x x
Osteomalacia postmarketing x x x
Pancreatitis postmarketing x x x
Polyuria postmarketing x x x
Proteinuria postmarketing x x x
Renal failure postmarketing x x x
Rhabdomyolysis postmarketing x x x
Urinary tract disorder postmarketing x x x
Hypophosphataemia postmarketing x x x
Amylase increased postmarketing x x x
Creatinine increased postmarketing x x x
Muscular weakness postmarketing x x x
Bone pain postmarketing x x x
Nephrogenic diabetes insipidus postmarketing x x x
Malnutrition postmarketing x x x
Unspecified disorder of skin and subcutaneous tissue postmarketing x x x
Hepatobiliary disease postmarketing x x x
Renal impairment postmarketing x x x
Hepatic steatosis postmarketing x x x
Anxiety x x x
Arthralgia x x x
Mental disorder x x x
Hepatitis B x
Hepatomegaly x x x
Lipodystrophy x x x
Metabolic disorder x x x
Nervous system disorder x x x
Serum creatinine increased x x
Infestation NOS x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

tenofovir

Side effects:71
Source:FDA Structured Product Label

TENOFOVIR ANHYDROUS

Side effects:74
Source:FDA Structured Product Label

TENOFOVIR ANHYDROUS

Side effects:75
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label